Drug intelligence / Profile preview

NeoTrace 4

Development stage: Unknown
Lead developer: American Regent
Modality: Small Molecules
Administration: Intravenous

Overview

NeoTrace 4 is an intravenous trace element formulation developed by SciGen, specifically approved in South Korea for use in oncology. It contains four essential trace elements: zinc, copper, manganese, and chromium. These elements are provided as additives to total parenteral nutrition (TPN) solutions to prevent or treat deficiencies in patients who are unable to receive adequate nutrition orally or enterally. Each element acts as a critical cofactor for various metabolic processes, including enzyme function, glucose metabolism, and cellular repair, which are often compromised in cancer patients undergoing intensive treatment.

Brand names: NeoTrace 4NeoTrace4NeoTrace-4
Other names: trace elements injectiontrace elements

Beyond the preview

Go deeper on NeoTrace 4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoTrace 4.

Explore the full profile